Overview

Attenuation Of Hemodynamic Response To Laryngoscopy. Role Of Dexmedetomidine. A Dose Finding Study

Status:
Completed
Trial end date:
2021-12-13
Target enrollment:
Participant gender:
Summary
Two doses of Dexmedetomidine (0.5 µ/kg and 0.75 µ/kg) will be used to attenuate the stress response to laryngoscopy in American Society of Anesthesiology, physical class I patients which will be compared with the placebo-controlled group.
Phase:
Phase 4
Details
Lead Sponsor:
Sindh Institute of Urology and Transplantation
Treatments:
Dexmedetomidine